To enable the use of patient-derived tumoroids in diagnosis and personalized therapy, we aim to develop a new kind of tumoroid assay that produces reliable results without the need of long tumoroid expansion. We will miniaturize standard drug screening assays and focus on readouts from individual organoids. To this end, we will integrate recent advances in microfluidics, tumoroid technology and imaging to deliver detailed predictions of treatment outcomes for individual patients. In close collaboration with Inselspital of Bern and UBERN, we will apply our technology to establish a personalized prostate and bladder cancer assay, which produces a detailed susceptibility profile of each tumor within the ambitious timeline of 14 days after biopsy.